Lit­tle Cona­tus' No­var­tis-part­nered liv­er drug suf­fers third straight de­feat, but CEO Men­to is still hold­ing out hope

7 years ago
People
R&D

RIP amy­loid be­ta the­o­ry? Nope. Bio­gen part­ner launch­es a new PhI­II be­fore ad­u­canum­ab's corpse turned cold

7 years ago
Bioregnum
Opinion

J&J mops up $900M in waste, writ­ing off the last big chunk of the $1.75B it spent to ac­quire Alios

7 years ago
Deals

Shang­hai-based can­cer drug­mak­er Ab­bisko lines up $42M B round as it makes a leap for the clin­ic

7 years ago
Financing
China

Hard-charg­ing GSK re­search chief Hal Bar­ron touts im­proved an­ti-BC­MA da­ta, aim­ing for fast ap­pli­ca­tions

7 years ago
R&D

$757M and 5 years lat­er, Cel­gene aban­doned a biotech part­ner, trig­ger­ing lay­offs

7 years ago
People
R&D

Found­ing For­ma CEO Steve Tre­gay fol­lows 61 staffers out the ex­it, re­placed by Genen­tech strat­e­gy vet

7 years ago
People

Feng Zhang, heavy­weight col­lab­o­ra­tors un­veil lat­est CRISPR up­start — a di­ag­nos­tic com­pa­ny

7 years ago
Startups

Roivan­t's rare dis­ease shop cap­tures FDA des­ig­na­tions; Chi­na biotech lands $18M launch round

7 years ago
News Briefing

Brex­it who? Record in­vest­ment last year fu­els big spike in reg­is­tered UK biotech firms

7 years ago
Financing
R&D

Bil­lion­aire Bertarel­li's Way­point steers al­ler­gy drug­mak­er Stal­ler­genes Greer pri­vate in $832M buy­out deal

7 years ago
Deals

As gener­ic en­try looms for its cash cow, Jazz wins FDA nod for fol­low-up sleep dis­or­der drug

7 years ago
Pharma

Bio­gen's Alzheimer's drug ad­u­canum­ab im­plodes in a PhI­II dis­as­ter — putting them at a per­ilous cross­roads

7 years ago
R&D

Faster, cheap­er, bet­ter? Post-buy­out deal Cel­gene jumps in­to AI al­liance with a $25 mil­lion bet on speed­ing dis­cov­ery ...

7 years ago
AI

NASH drug in hand, Mer­ck forges ahead with 2-year ex­ten­sion of NGM Bio col­lab­o­ra­tion deal

7 years ago
R&D
Pharma

To tack­le soar­ing pre­scrip­tion drug costs, Cana­da cre­ates new agency to ne­go­ti­ate prices; DMC clears phI­II test­ing of ...

7 years ago
News Briefing

EMA sounds its own safe­ty alarm for Pfiz­er block­buster, but they’re al­so not forc­ing a lim­it on dos­ing — yet

7 years ago
Pharma

With eye on rev­enue sta­bi­liza­tion, Gilead takes 4.9% hike on a bas­ket of drugs

7 years ago
Pharma

Flag­ship ties up a mon­ster $824M fund to back a new wave of biotech star­tups seed­ed in their lab

7 years ago
Financing

Pfiz­er lines up a po­ten­tial $687M rare dis­ease buy­out to ex­pand its stake in the hot gene ther­a­py field

7 years ago
Pharma
Cell/Gene Tx

Glax­o­SmithK­line sets its sights on a quick leap in­to the big PD-1/L1 game — will any­one no­tice?

7 years ago
R&D

Fol­low­ing Syn­tim­mune buy­out, Alex­ion antes up $25M to dou­ble down on an­ti-FcRn path­way

7 years ago
Pharma

Pfiz­er, Mer­ck KGaA throw in the tow­el on an­oth­er Baven­cio PhI­II as once bright hopes shriv­el fast

7 years ago
R&D

FDA ap­proves trail­blaz­ing post­par­tum de­pres­sion ther­a­py, in cru­cial mile­stone for wom­en's health

7 years ago
Pharma
First page Previous page 965966967968969970971 Next page Last page
A service from the Financial Times